Frontiers in Endocrinology · Nov 10, 2026
Relationship between Dipeptidyl Peptidase-4 Inhibitors Use and Risk of Dementia: A Population-Based Cohort Study
By Tung-Han Tsai, Zong-Han Lin, Shuo-Yan Gau et al.
Background: Dipeptidyl peptidase-4 inhibitors (DPP-4i) are used to treat patients with diabetes mellitus (DM). DPP-4i are associated with dementia in patients with DM. This study aimed to investigate the association between DPP-4i and dementia among patients with DM. Methods: This study was a secondary analysis based on the nationwide database in Taiwan. Patients with new-onset DM who were treated with either a DPP-4i or sulfonylurea from 2008 to 2017 were included in this study. The cumulative defined daily dose (cDDD) was used to assess DPP-4i use. Patients were divided according to cDDD: Q3. Patients who received a sulfonylurea comprised the comparison group. With adjustment for sex, age, income, urbanization level, and comorbidities, the Cox proportional hazard model was used to estimate the risk of dementia associated with DPP-4i use. Result: There were 57 008 patients with DPP-4i use and 114 016 patients with sulfonylurea use. Compared with sulfonylurea users, low-to-intermediate cumulative exposure to DPP-4i was associated with an increased risk of dementia (Q3) demonstrated a reduction in dementia risk (aHR, 0.42; 95% CI, 0.35–0.50). Across individual DPP-4i, also a decreased risk of dementia with high cumulative exposure (>Q3), including linagliptin (aHR, 0.35; 95% CI, 0.24–0.51), saxagliptin (aHR, 0.52; 95% CI, 0.36–0.75), sitagliptin (aHR, 0.61; 95% CI, 0.51–0.72), and vildagliptin (aHR, 0.49; 95% CI, 0.35–0.70). Conclusion: Among patients with DM, low-to-intermediate cumulative exposure was associated with an increased risk of dementia, whereas the highest cumulative exposure (>Q3) to DPP-4i was associated with a significantly reduced risk. Prospective randomized clinical trials and mechanistic studies are warranted to confirm these findings.